FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2249534610> ?p ?o ?g. }

• W2249534610 abstract "5007 Background: While the majority of patients with vulvar cancer can be cured by surgery alone, women with lymph-node metastases often show unfavorable outcome. Improved treatment strategies are therefore strongly needed. Methods: Patients with primary squamous-cell vulvar cancer treated at 29 gynecologic cancer centers in Germany between 1998 and 2008 were included in a centralized database and analyzed retrospectively. Results: A total of 1,637 patients were documented with a median follow-up of 121 months. UICC-Stage distribution was 597 (36.5 %) T1, 816 (49.8 %) T2, 160 (9.8 %) T3 and 31 (1.9 %) T4, 33 (2.0 %) were missing. 491 patients had lymph-node metastasis to the groins (N+). 214 N+ patients (43.6 %) developed recurrent disease within a median of 21.4 months. 190 N+ patients (38.7%) died, median overall survival (OS) was 43.4 months, compared to 212 months for node-negative patients. An increasing number of metastatic lymph-nodes was associated with shorter OS: 169 (34.4%) patients had 1, 101 (20.6%) patients 2, 62 (12.6%) patients 3 and 86 (17.5%) patients >3 positive lymph-nodes, with a corresponding OS of 22.4, 17.2, 18.4 and 10.2 months, respectively (for 73 patients the number of nodes was not available). 240 N+ patients were treated with adjuvant radiotherapy (85.8%) or radiochemotherapy (14.2%). Median OS in these patients was significantly longer (66.9 months) compared to N+ patients without adjuvant treatment (35.7 months), the corresponding hazard ratio (HR) was 0.72 (95 % CI: 0.53 - 0.97 p = 0.029). This impact on OS remained consistent in multivariate analysis adjusted for age, ECOG, stage, grading, invasion depth and number of positive nodes (HR 0.68; 95% CI: 0.49 - 0.94 p = 0.020) and was observed irrespective of the number of affected nodes. Conclusions: To this day, this is the largest multicenter study on vulvar cancer. Our findings strongly suggest that the unfavorable prognosis of patients with node positive vulvar cancer can be improved by adjuvant therapy irrespective of the number of affected nodes. As adjuvant radiochemotherapy was shown to be superior to radiotherapy alone in many other squamous cell carcinomas, we are preparing a prospective phase III trial in node-positive vulvar cancer (AGO-CaRE 2 trial)." @default.
• W2249534610 created "2016-06-24" @default.
• W2249534610 creator A5001140861 @default.
• W2249534610 creator A5003275560 @default.
• W2249534610 creator A5013506154 @default.
• W2249534610 creator A5016529001 @default.
• W2249534610 creator A5016766526 @default.
• W2249534610 creator A5018389594 @default.
• W2249534610 creator A5022527560 @default.
• W2249534610 creator A5028895212 @default.
• W2249534610 creator A5043298897 @default.
• W2249534610 creator A5047398107 @default.
• W2249534610 creator A5047695952 @default.
• W2249534610 creator A5050467390 @default.
• W2249534610 creator A5056412323 @default.
• W2249534610 creator A5069415804 @default.
• W2249534610 creator A5072966066 @default.
• W2249534610 creator A5078567055 @default.
• W2249534610 creator A5080743757 @default.
• W2249534610 creator A5081837620 @default.
• W2249534610 creator A5084392138 @default.
• W2249534610 creator A5087921336 @default.
• W2249534610 creator A5088082888 @default.
• W2249534610 date "2012-05-20" @default.
• W2249534610 modified "2023-10-01" @default.
• W2249534610 title "Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study." @default.
• W2249534610 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.5007" @default.
• W2249534610 hasPublicationYear "2012" @default.
• W2249534610 type Work @default.
• W2249534610 sameAs 2249534610 @default.
• W2249534610 citedByCount "5" @default.
• W2249534610 countsByYear W22495346102013 @default.
• W2249534610 countsByYear W22495346102014 @default.
• W2249534610 countsByYear W22495346102021 @default.
• W2249534610 crossrefType "journal-article" @default.
• W2249534610 hasAuthorship W2249534610A5001140861 @default.
• W2249534610 hasAuthorship W2249534610A5003275560 @default.
• W2249534610 hasAuthorship W2249534610A5013506154 @default.
• W2249534610 hasAuthorship W2249534610A5016529001 @default.
• W2249534610 hasAuthorship W2249534610A5016766526 @default.
• W2249534610 hasAuthorship W2249534610A5018389594 @default.
• W2249534610 hasAuthorship W2249534610A5022527560 @default.
• W2249534610 hasAuthorship W2249534610A5028895212 @default.
• W2249534610 hasAuthorship W2249534610A5043298897 @default.
• W2249534610 hasAuthorship W2249534610A5047398107 @default.
• W2249534610 hasAuthorship W2249534610A5047695952 @default.
• W2249534610 hasAuthorship W2249534610A5050467390 @default.
• W2249534610 hasAuthorship W2249534610A5056412323 @default.
• W2249534610 hasAuthorship W2249534610A5069415804 @default.
• W2249534610 hasAuthorship W2249534610A5072966066 @default.
• W2249534610 hasAuthorship W2249534610A5078567055 @default.
• W2249534610 hasAuthorship W2249534610A5080743757 @default.
• W2249534610 hasAuthorship W2249534610A5081837620 @default.
• W2249534610 hasAuthorship W2249534610A5084392138 @default.
• W2249534610 hasAuthorship W2249534610A5087921336 @default.
• W2249534610 hasAuthorship W2249534610A5088082888 @default.
• W2249534610 hasConcept C121608353 @default.
• W2249534610 hasConcept C126322002 @default.
• W2249534610 hasConcept C143998085 @default.
• W2249534610 hasConcept C2777180808 @default.
• W2249534610 hasConcept C2777863537 @default.
• W2249534610 hasConcept C2777982462 @default.
• W2249534610 hasConcept C2780370617 @default.
• W2249534610 hasConcept C2780849966 @default.
• W2249534610 hasConcept C71924100 @default.
• W2249534610 hasConceptScore W2249534610C121608353 @default.
• W2249534610 hasConceptScore W2249534610C126322002 @default.
• W2249534610 hasConceptScore W2249534610C143998085 @default.
• W2249534610 hasConceptScore W2249534610C2777180808 @default.
• W2249534610 hasConceptScore W2249534610C2777863537 @default.
• W2249534610 hasConceptScore W2249534610C2777982462 @default.
• W2249534610 hasConceptScore W2249534610C2780370617 @default.
• W2249534610 hasConceptScore W2249534610C2780849966 @default.
• W2249534610 hasConceptScore W2249534610C71924100 @default.
• W2249534610 hasLocation W22495346101 @default.
• W2249534610 hasOpenAccess W2249534610 @default.
• W2249534610 hasPrimaryLocation W22495346101 @default.
• W2249534610 hasRelatedWork W117127195 @default.
• W2249534610 hasRelatedWork W1838898196 @default.
• W2249534610 hasRelatedWork W1915745373 @default.
• W2249534610 hasRelatedWork W1976117633 @default.
• W2249534610 hasRelatedWork W2002067767 @default.
• W2249534610 hasRelatedWork W2036492806 @default.
• W2249534610 hasRelatedWork W2071753584 @default.
• W2249534610 hasRelatedWork W2081153580 @default.
• W2249534610 hasRelatedWork W2108324926 @default.
• W2249534610 hasRelatedWork W2139943176 @default.
• W2249534610 hasRelatedWork W2409059906 @default.
• W2249534610 hasRelatedWork W2888236249 @default.
• W2249534610 hasRelatedWork W2897555518 @default.
• W2249534610 hasRelatedWork W2944285162 @default.
• W2249534610 hasRelatedWork W2965363634 @default.
• W2249534610 hasRelatedWork W2972919736 @default.
• W2249534610 hasRelatedWork W3174538191 @default.
• W2249534610 hasRelatedWork W3200392540 @default.
• W2249534610 hasRelatedWork W377076876 @default.
• W2249534610 hasRelatedWork W2558439832 @default.
• W2249534610 isParatext "false" @default.
• W2249534610 isRetracted "false" @default.
• W2249534610 magId "2249534610" @default.

• next